A new research perspective was published in Volume 13 of Oncoscience on June 3, 2026, titled "The dual axis of tumorigenesis: ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients ...
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results